Mark L. Tykocinski
President at Thomas Jefferson University
Profile
Mark L.
Tykocinski was the founder of KAHR Medical Ltd.
founded in 2005, where he held the title of Research Officer.
Currently, he is the President of Thomas Jefferson University.
Previously, he held the position of Senior Vice President at Thomas Jefferson University, Principal at the University of Pennsylvania, Dean at Sidney Kimmel Medical College, and President at the American Society for Investigative Pathology.
Mark L. Tykocinski active positions
| Companies | Position | Start |
|---|---|---|
| Thomas Jefferson University | President | - |
Former positions of Mark L. Tykocinski
| Companies | Position | End |
|---|---|---|
American Society for Investigative Pathology
 American Society for Investigative Pathology BiotechnologyHealth Technology The American Society for Investigative Pathology operates as a biotechnology company. | President | - |
| University of Pennsylvania | Corporate Officer/Principal | - |
| Sidney Kimmel Medical College | Corporate Officer/Principal | - |
| Thomas Jefferson University | Corporate Officer/Principal | - |
KAHR Medical Ltd.
 KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Founder | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
American Society for Investigative Pathology
American Society for Investigative Pathology BiotechnologyHealth Technology The American Society for Investigative Pathology operates as a biotechnology company. | Health Technology |
- Stock Market
- Insiders
- Mark L. Tykocinski
